N/A
Manufactured by Azurity Pharmaceuticals, Inc.
3,842 FDA adverse event reports analyzed
Last updated: 2026-04-15
AMPHETAMINE SULFATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Azurity Pharmaceuticals, Inc.. The most commonly reported adverse reactions for AMPHETAMINE SULFATE include TOXICITY TO VARIOUS AGENTS, DRUG ABUSE, COMPLETED SUICIDE, CARDIAC ARREST, DRUG INEFFECTIVE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AMPHETAMINE SULFATE.
Out of 2,128 classified reports for AMPHETAMINE SULFATE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 3,842 FDA FAERS reports that mention AMPHETAMINE SULFATE. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include TOXICITY TO VARIOUS AGENTS, DRUG ABUSE, COMPLETED SUICIDE, CARDIAC ARREST, DRUG INEFFECTIVE, CARDIO-RESPIRATORY ARREST. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Azurity Pharmaceuticals, Inc. in connection with AMPHETAMINE SULFATE. Always verify the specific product and NDC with your pharmacist.